Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 18,664 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Clear all
Completed Not applicable Interventional

Nature as a Buffer Among People With Chronic Pain

NCT03153891
View directory record Official record
Conditions
Chronic Pain
Interventions
Natural Environment, Built Environment
Other
Lead sponsor
Cornell University
Other
Eligibility
60 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02299518
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
mitoxantrone hydrochloride, etoposide, cytarabine, selinexor, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Alice Mims
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

NCT06015282
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aQIVc, licensed QIVr, licensed aQIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
7,741 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
51
States / cities
Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 1 Interventional

Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors

NCT00426582
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Norwalk, Connecticut • Rockville, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 29, 2026, 5:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of Reward Processing in Prenatally Exposed Adolescents and Young Adults

NCT03268759
View directory record Official record
Conditions
Pre-natal Cocaine Exposure, Risk-Taking
Interventions
fMRI
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 20 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 29, 2026, 5:20 PM EDT
Recruiting Phase 1 Interventional

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

NCT07297979
View directory record Official record
Conditions
Ewing Sarcoma
Interventions
Xaluritamig
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 5:20 PM EDT
Terminated Phase 1 Interventional

Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

NCT04397679
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy (IMRT), Temozolomide, Chloroquine, Tumor Treating Fields Therapy (TTF)
Radiation · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 29, 2026, 5:20 PM EDT
Recruiting Phase 3 Interventional

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

NCT07089888
View directory record Official record
Conditions
Tophaceous Gout
Interventions
Allopurinol, Dotinurad
Drug
Lead sponsor
Crystalys Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
96
States / cities
Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Mobile Tai Chi Platform for Fall Prevention in Older Adults - Phase II

NCT05006261
View directory record Official record
Conditions
Healthy Aging
Interventions
Tele-Tai Chi
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 29, 2026, 5:20 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

NCT05518500
View directory record Official record
Conditions
Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
Interventions
Flu Vaccine (Year 1), Flu Vaccine (Year 2), Flu Vaccine (Year 3), Flu Vaccine (Year 4)
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
65 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 29, 2026, 5:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users

NCT06909500
View directory record Official record
Conditions
Nicotine Dependence, Tobacco-Related Carcinoma
Interventions
Smartphone app, Text Message, Survey Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 30 Years
Enrollment
1,178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 5:20 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Tennessee Youth Prepared for Success

NCT06001892
View directory record Official record
Conditions
Adolescent Behavior, Adolescent Problem Behavior, Risk Reduction
Interventions
Tennessee Youth Prepared for Success
Behavioral
Lead sponsor
Centerstone Research Institute
Other
Eligibility
14 Years to 19 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 4 Interventional Results available

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

NCT00520234
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Caspofungin, Normal Saline
Drug
Lead sponsor
Mycoses Study Group
Network
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

NCT03829332
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 29, 2026, 5:20 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

NCT03165721
View directory record Official record
Conditions
Paraganglioma, Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Renal Neoplasms, Pheochromocytoma
Interventions
SGI-110 (guadecitabine)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 29, 2026, 5:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mental Effort During Low Load Resistance Training in Older Adults

NCT07687316
View directory record Official record
Conditions
Seniors, Old Age, Sarcopenia
Interventions
Low Intensity Resistance Training with Maximal Mental Effort, Low Intensity Resistance Training
Behavioral
Lead sponsor
Kennesaw State University
Other
Eligibility
65 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kennesaw, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 4 Interventional Results available

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

NCT04294147
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Erenumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Waterbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

NCT02214147
View directory record Official record
Conditions
Advanced Solid Tumors, Relapsed/Refractory Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Miami, Florida • Chicago, Illinois • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ICC-1132 - Candidate Vaccine Against P Falciparum Malaria

NCT00587249
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Malaria ICC-1132, Alhydrogel
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 29, 2026, 5:20 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

NCT04101838
View directory record Official record
Conditions
Influenza
Interventions
Fluzone, Flucelvax, Fluzone High-Dose, Fluad
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 3 Interventional Results available

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745638
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

NCT00670358
View directory record Official record
Conditions
Lymphoma
Interventions
pegfilgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, lenalidomide, prednisone, vincristine sulfate, polymorphism analysis, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 29, 2026, 5:20 PM EDT
Completed Not applicable Interventional

Genius PillBox Study

NCT06901258
View directory record Official record
Conditions
Older Adults (65 Years and Older)
Interventions
Genius Pillbox
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 29, 2026, 5:20 PM EDT